Title : ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.

Pub. Date : 2015 Aug 28

PMID : 26050198






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 ZD6474, a small molecule VEGFR and EGFR tyrosine kinase inhibitor, has been considered as a promising tumor-targeted drug in various malignancies. vandetanib epidermal growth factor receptor Homo sapiens
2 EGFR and cyclooxygenase-2 (COX-2) were found overexpressed in osteosarcoma in previous reports, so here we tried to explore the anti-osteosarcoma effect of ZD6474 alone or combination with celecoxib, a COX-2 inhibitor. vandetanib epidermal growth factor receptor Homo sapiens
3 The data demonstrated that ZD6474 inhibited the growth of osteosarcoma cells, and promoted G1-phase cell cycle arrest and apoptosis by inhibiting the activity of EGFR tyrosine kinase, and consequently suppressing its downstream PI3k/Akt and MAPK/ERK pathway. vandetanib epidermal growth factor receptor Homo sapiens